(Reuters) – Three new conditions reported by a small number of people after vaccination with COVID-19 shots from Pfizer and Moderna are being studied to assess if they may be possible side-effects, Europe’s drugs regulator said on Wednesday.
According to the regulator, three concerns are being studied by the safety committee of the European Medicines Agency (EMA):
- Erythema multiforme, a form of allergic skin reaction;
- glomerulonephritis or kidney inflammation;
- and nephrotic syndrome, a renal disorder characterised by heavy urinary protein losses.
Pfizer, by far the biggest supplier of COVID-19 vaccines to the European Union, and Moderna did not immediately respond to Reuters requests for comment.
Last month, the EMA found a possible link between very rare heart inflammation and the mRNA vaccines.
However, the European regulator and the World Health Organization have stressed that benefits from these vaccines outweigh any risks … READ MORE.
“The success of the mRNA technology used by the two vaccines has been a turning point for the pandemic and the scientific community, but some rare side-effects are being studied as more people are inoculated globally.” – Channel News Asia, Aug 11, 2021
Pharmaceutical firms rake in billions with COVID-19 jabs
CHANNEL NEWS ASIA, 09 Aug 2021
PARIS: Covid vaccines have brought billions of dollars to the coffers of pharmaceutical companies.
Germany’s BioNTech, maker of the pioneering mRNA jab along with partner Pfizer, raised its vaccine revenue forecast for 2021 in its latest earnings report on Monday (Aug 9).
Here are the numbers for the companies that publish financial results:
Biggest winners: Pfizer and BioNTech
US firm Pfizer and BioNTech got a headstart over rivals as they were the first in the western world to announce positive results from clinical trials of their vaccine last year.
They were also first to get authorisation from US and European Union regulators to sell their shot.
Pfizer has earned more than its competitors, raking in US$10.8 billion (9.2 billion euros) in the first half of this year.
The US company has raised its outlook for 2021, expecting to make US$33.5 billion in sales for the full year.
BioNTech reported on Tuesday revenues of US$7.3 billion euros in the first half. Unlike its larger partner, the company’s only product on sale is the coronavirus vaccine.
BioNTech expects vaccine revenues to reach 15.9 billion euros for the full year, up from a previous estimate of 9.8 billion euros.
Israeli survey finds 3rd Pfizer COVID-19 vaccine dose has similar side effects to 2nd
Moderna’s COVID-19 shot 93% effective 4 to 6 months after second dose
Moderna the other mRNA champion … READ MORE.
